Stevanato Group S.p.A.

NYSE•STVN

CEO: Mr. Franco Stevanato

セクター: Healthcare

業種: Medical - Instruments & Supplies

上場日: 2021-07-16

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

連絡先情報

Via Molinella, 17, Piombino Dese, PD, 35017, Italy

39-04-99-31-811

www.stevanatogroup.com

時価総額

$4.34B

PER (TTM)

26.8

26.9

配当利回り

0.4%

52週高値

$28.00

52週安値

$13.91

52週レンジ

14%

順位29Top 17.8%

5.2

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

堅調 • 5.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$399.64M+0.00%

直近4四半期の推移

EPS

$0.20+0.00%

直近4四半期の推移

フリーCF

$0.00+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Revenue Growth Revenue 1,186.3M EUR, up 7.4% from 1,104.0M EUR, driven by strong demand in high-value solutions and biopharmaceutical segments.

Operating Profit Surge Operating profit 198.8M EUR, up 23.4% from 161.1M EUR, reflecting improved operating leverage and higher gross profit margins.

High-Value Solutions Expansion High-value solutions revenue 546.4M EUR, up 29.4% from 422.3M EUR, representing 46% of total revenue, up from 38.3%.

Net Profit Growth Net profit 139.8M EUR, up 18.7% from 117.8M EUR, demonstrating strong operational performance and effective cost management strategies.

リスク要因

Internal Control Weaknesses Identified material weaknesses in internal control over financial reporting, potentially impacting investor confidence and accuracy of financial reporting.

Geopolitical Supply Risks Tensions between China and U.S. threaten supply chain stability, potentially disrupting operations and increasing costs for critical materials.

Currency Exchange Volatility Net loss of 15.7M EUR from foreign exchange differences in 2025, driven by U.S. Dollar devaluation against the Euro.

Regulatory Compliance Pressure Complex global regulations, including GDPR and potential new tariffs, increase compliance costs and operational risks across international jurisdictions.

見通し

Capacity Expansion Strategy Prioritizing ramp-up of manufacturing facilities in Fishers, U.S., and Latina, Italy, to support growing demand for high-value solutions.

R&D Investment Focus Investing 25.4M EUR in R&D to drive innovation in drug delivery systems and maintain competitive edge in biopharmaceutical markets.

Digital Transformation Program Continuing digital transformation to enhance operational efficiency, with 95% of workforce integrated into cloud-based ERP systems by 2026.

同業比較

売上高 (TTM)

ALC

$10.40B

+4.9%

AVTR

$6.55B

-3.4%

RMD

$5.40B

+9.6%

粗利益率 (最新四半期)

AXSM

93.7%

+1.1pp

ATRC

74.4%

+0.6pp

COO

67.9%

-10.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ALC	$40.22B	41.2	4.4%	16.6%
RMD	$37.27B	25.2	24.8%	11.8%
WST	$17.60B	35.8	16.7%	7.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

14.0%

安定成長

4四半期純利益CAGR

25.3%

収益性の大幅な改善

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月7日

EPS:$0.15

売上高:$315.15M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし